Guanfacine extended release for the treatment of attention-deficit/hyperactivity disorder in children and adolescents

Bibliography

• Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007;46(7):894-921
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention, United States. Increasing prevalence of parent-reported attention-deficit/hyperactivity disorder among children---United States, 2003 and 2007. MMWR Morb Mortal Wkly Rep 2010;59:1439-43
   Google Scholar
• Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 2006;163(4):716-23
   PubMed Web of Science ®Google Scholar
• Polanczyk G, de Lima MS, Horta BL, et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007;164(6):942-8
   PubMed Web of Science ®Google Scholar
• Barkley RA, Fischer M, Smallish L, et al. Young adult outcome of hyperactive children: adaptive functioning in major life activities. J Am Acad Child Adolesc Psychiatry 2006;45(2):192-202
   PubMed Web of Science ®Google Scholar
• Klein RG, Mannuzza S, Olazagasti MA, et al. Clinical and functional outcome of childhood attention-deficit/hyperactivity disorder 33 years later. Arch Gen Psychiatry 2012;69(12):1295-303
   PubMed Web of Science ®Google Scholar
• Barkley RA, Fischer M, Smallish L, et al. Young adult follow-up of hyperactive children: antisocial activities and drug use. J Child Psychol Psychiatry 2004;45(2):195-211
   PubMed Web of Science ®Google Scholar
• Barkley RA, Fischer M. The unique contribution of emotional impulsiveness to impairment in major life activities in hyperactive children as adults. J Am Acad Child Adolesc Psychiatry 2010;49(5):503-13
   PubMed Web of Science ®Google Scholar
• Doshi JA, Hodgkins P, Kahle J, et al. Economic impact of childhood and adult attention-deficit/hyperactivity disorder in the United States. J Am Acad Child Adolesc Psychiatry 2012;51(10):990-1002. e2
   PubMed Web of Science ®Google Scholar
• Le HH, Hodgkins P, Postma MJ, et al. Economic impact of childhood/adolescent ADHD in a European setting: the Netherlands as a reference case. Eur Child Adolesc Psychiatry 2013. [ Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Feldman HM, Reiff MI. Clinical practice. Attention deficit-hyperactivity disorder in children and adolescents. N Engl J Med 2014;370(9):838-46
   Google Scholar
• Kelly C, Biswal BB, Craddock RC, et al. Characterizing variation in the functional connectome: promise and pitfalls. Trends Cog Sci 2012;16(3):181-8
   PubMed Web of Science ®Google Scholar
• Castellanos FX, Proal E. Large-scale brain systems in ADHD: beyond the prefrontal-striatal model. Trends Cog Sci 2012;16(1):17-26
   PubMed Web of Science ®Google Scholar
• Shaw P, Eckstrand K, Sharp W, et al. Attention-deficit/hyperactivity disorder is characterized by a delay in cortical maturation. Proc Natl Acad Sci USA 2007;104(49):19649-54
   PubMed Web of Science ®Google Scholar
• Shaw P, Lalonde F, Lepage C, et al. Development of cortical asymmetry in typically developing children and its disruption in attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2009;66(8):888-96
   Google Scholar
• Barkley RA. Attention-deficit hyperactivity disorder: a handbook for diagnosis and treatment. 3rd edition. Guilford; NY, USA: 2006
   Google Scholar
• Faraone SV, Mick E. Molecular genetics of attention deficit hyperactivity disorder. Psychiatr Clin North Am 2010;33(1):159-80
   PubMed Web of Science ®Google Scholar
• Devilbiss DM, Berridge CW. Cognition-enhancing doses of methylphenidate preferentially increase prefrontal cortex neuronal responsiveness. Biol Psychiatry 2008;64(7):626-35
   Google Scholar
• Gamo NJ, Wang M, Arnsten AF. Methylphenidate and atomoxetine enhance prefrontal function through alpha2-adrenergic and dopamine D1 receptors. J Am Acad Child Adolesc Psychiatry 2010;49(10):1011-23
   PubMed Web of Science ®Google Scholar
• Spencer RC, Klein RM, Berridge CW. Psychostimulants act within the prefrontal cortex to improve cognitive function. Biol Psychiatry 2012;72(3):221-7
   PubMed Web of Science ®Google Scholar
• Bukstein OG, Head J. Guanfacine ER for the treatment of adolescent attention-deficit/hyperactivity disorder. Expert Opin Pharmacother 2012;13(15):2207-13
   PubMed Web of Science ®Google Scholar
• Connor DF. Stimulants. In: Barkley RA, editor. Attention-deficit hyperactivity disorder: a handbook for diagnosis and treatment. Guildford; NY, USA: 2006. p. 608-47
   Google Scholar
• Greenhill LL, Pliszka S, Dulcan MK, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002;41(2 Suppl):26S-49S
   PubMed Web of Science ®Google Scholar
• Sorkin EM, Heel RC. Guanfacine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension. Drugs 1986;31(4):301-36
   PubMed Web of Science ®Google Scholar
• Arnsten AF, Steere JC, Hunt RD. The contribution of alpha 2-noradrenergic mechanisms of prefrontal cortical cognitive function. Potential significance for attention-deficit hyperactivity disorder. Arch Gen Psychiatry 1996;53(5):448-55
   PubMed Web of Science ®Google Scholar
• Hunt RD, Arnsten AF, Asbell MD. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995;34(1):50-4
   PubMed Web of Science ®Google Scholar
• Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 2001;158(7):1067-74
   PubMed Web of Science ®Google Scholar
• Cruz MP. Guanfacine extended-release tablets (intuniv), a nonstimulant selective alpha(2A)-adrenergic receptor agonist for attention-deficit/hyperactivity disorder. P T 2010;35(8):448-51
   PubMedGoogle Scholar
• Engberg G, Eriksson E. Effects of alpha 2-adrenoceptor agonists on locus coeruleus firing rate and brain noradrenaline turnover in N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ)-treated rats. Naunyn Schmiedebergs Arch Pharmacol 1991;343(5):472-7
   Google Scholar
• U’Prichard DC, Bechtel WD, Rouot BM, et al. Multiple apparent alpha-noradrenergic receptor binding sites in rat brain: effect of 6-hydroxydopamine. Mol Pharmacol 1979;16(1):47-60
   Google Scholar
• Wang M, Ramos BP, Paspalas CD, et al. Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell 2007;129(2):397-410
   PubMed Web of Science ®Google Scholar
• Arnsten AF, Jin LE. Guanfacine for the treatment of cognitive disorders: a century of discoveries at Yale. Yale J Biol Med 2012;85(1):45-58
   PubMedGoogle Scholar
• Kim S, Bobeica I, Gamo NJ, et al. Effects of alpha-2A adrenergic receptor agonist on time and risk preference in primates. Psychopharmacol (Berl) 2012;219(2):363-75
   PubMed Web of Science ®Google Scholar
• Arnsten AF. The use of alpha2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorder. Expert Rev Neurother 2010;10:1595-605
   PubMed Web of Science ®Google Scholar
• Arnsten AFT. Stress signaling pathways that impair prefrontal cortex structure and function. Nat Rev Neurosci 2009;32:267-87
   Google Scholar
• Boellner SW, Pennick M, Fiske K, et al. Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder. Pharmacotherapy 2007;27(9):1253-62
   PubMed Web of Science ®Google Scholar
• Sallee F, Connor DF, Newcorn JH. A review of the rationale and clinical utilization of alpha2-adrenoceptor agonists for the treatment of attention-deficit/hyperactivity and related disorders. J Child Adolesc Psychopharmacol 2013;23(5):308-19
   Google Scholar
• Swearingen D, Pennick M, Shojaei A, et al. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults. Clin Ther 2007;29(4):617-25
   Google Scholar
• Roesch B, Corcoran ME, Fetterolf J, et al. Pharmacokinetics of coadministered guanfacine extended release and lisdexamfetamine dimesylate. Drugs R D 2013;13(2):119-28
   Google Scholar
• Roesch B, Corcoran M, Haffey M, et al. Pharmacokinetics of coadministration of guanfacine extended release and methylphenidate extended release. Drugs R D 2013;13(1):53-61
   Google Scholar
• Wilson MF, Haring O, Lewin A, et al. Comparison of guanfacine versus clonidine for efficacy, safety and occurrence of withdrawal syndrome in step-2 treatment of mild to moderate essential hypertension. Am J Cardiol 1986;57(9):43E-9E
   Google Scholar
• Kisicki JC, Fiske K, Lyne A. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years. Clin Ther 2007;29(9):1967-79
   PubMed Web of Science ®Google Scholar
• Biederman J, Melmed RD, Patel A, et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 2008;121(1):e73-84
   PubMed Web of Science ®Google Scholar
• Sallee FR, McGough J, Wigal T, et al. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2009;48(2):155-65
   PubMed Web of Science ®Google Scholar
• DuPaul GJ, Power TJ, Anastopoulos AD, et al. ADHD rating scale - IV: checklists, norms, and clinical interpretation. Guilford Press; NY, USA: 1998
   Google Scholar
• Spencer TJ, Greenbaum M, Ginsberg LD, et al. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009;19(5):501-10
   PubMed Web of Science ®Google Scholar
• Wilens TE, Bukstein O, Brams M, et al. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2012;51(1):74-85. e2
   PubMed Web of Science ®Google Scholar
• Biederman J, Melmed RD, Patel A, et al. Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD. CNS Spectr 2008;13(12):1047-55
   PubMed Web of Science ®Google Scholar
• Sallee FR, Lyne A, Wigal T, et al. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2008;19(3):215-26
   Google Scholar
• Newcorn JH, Stein MA, Childress AC, et al. Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration. J Am Acad Child Adolesc Psychiatry 2013;52(9):921-30
   PubMed Web of Science ®Google Scholar
• Connor DF, Findling RL, Kollins SH, et al. Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial. CNS Drugs 2010;24(9):755-68
   PubMed Web of Science ®Google Scholar
• Connor DF, Rubin J. Guanfacine extended release in the treatment of attention deficit hyperactivity disorder in children and adolescents. Drugs Today (Barc) 2010;46(5):299-314
   Google Scholar
• Kollins SH, Lopez FA, Vince BD, et al. Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2011;21(2):111-20
   PubMed Web of Science ®Google Scholar
• Department of Health and Human Services FaDA, Office of Surveillance and Epidemiology. Pediatric postmardet adverse event review, guanfacine hydrochloride, extended-release. 2013. Available from: www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM367048.pdf2013
   Google Scholar
• ClinicalTrials.gov. database U.S. National Institutes of Health, Washington DC; 2014. Available from: http://clinicatrials.gov/ct2/results?term=guanfacine+ext3nded+release+AND+ADHD&Search=Search
   Google Scholar
• Hirota T, Schwartz S, Correll CU. Alpha-2 agonists for attention-deficit/hyperactivity disorder in youth: a systematic review and meta-analysis of monotherapy and add-on trials to stimulant therapy. J Am Acad Child Adolesc Psychiatry 2014;53(2):153-73
   PubMed Web of Science ®Google Scholar
• Schwartz S, Correll CU. Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression. J Am Acad Child Adolesc Psychiatry 2014;53(2):174-87
   PubMed Web of Science ®Google Scholar
• Connor DF, Grasso DJ, Slivinsky MD, et al. An open-label study of guanfacine extended release for traumatic stress symptoms in children and adolescents. J Child Adolesc Psychopharmacol 2013;23(4):244-51
   PubMed Web of Science ®Google Scholar
• Olfson M, Blanco C, Liu L, et al. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 2006;63(6):679-85
   PubMed Web of Science ®Google Scholar